慢性骨髄性白血病(CML)治療薬の世界市場:市場インサイト、疫学、市場予測

◆英語タイトル:Chronic Myelocytic Leukemia (CML) - Market Insights, Epidemiology and Market Forecast-2023
◆商品コード:DLVEP06060
◆発行会社(調査会社):DelveInsight
◆発行日:2016年9月
◆ページ数:約100
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後10営業日)
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single User(1名使用)USD4,950 ⇒換算¥564,300見積依頼/購入/質問フォーム
Site Price(同一国内共有可)USD9,900 ⇒換算¥1,128,600見積依頼/購入/質問フォーム
Enterprise Price(複数国内共有可)USD14,850 ⇒換算¥1,692,900見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規販売代理店です。DelveInsight社の概要及び新刊レポートはこちらでご確認いただけます。
当調査レポートでは、慢性骨髄性白血病(CML)治療薬の世界市場について調査・分析し、市場概要、医薬品概要、インサイト、疫学分析、市場規模予測データなどを含め、以下の構成でお届けいたします。
・慢性骨髄性白血病(CML)の概要
・病態生理
・慢性骨髄性白血病(CML)の症状
・慢性骨髄性白血病(CML)の病因
・慢性骨髄性白血病(CML)の診断
・慢性骨髄性白血病(CML)の治療
・上市品の概要
・医薬品の説明
・作用機序
・薬物動態学的特性
・特許情報
・慢性骨髄性白血病(CML)の疫学分析
・慢性骨髄性白血病(CML)治療薬の世界市場規模
・慢性骨髄性白血病(CML)治療薬の世界市場予測
・慢性骨髄性白血病(CML)治療薬のアメリカ市場規模
・慢性骨髄性白血病(CML)治療薬のアメリカ市場予測
・慢性骨髄性白血病(CML)治療薬のヨーロッパ市場規模
・慢性骨髄性白血病(CML)治療薬のヨーロッパ市場予測
(ドイツ、イギリス、フランス、イタリア、スペイン)
・慢性骨髄性白血病(CML)治療薬の日本市場規模
・慢性骨髄性白血病(CML)治療薬の日本市場予測
【レポートの概要】

Note*: This report requires 7-10 business days to complete.

DelveInsight’s Chronic Myelocytic Leukemia (CML) – Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Crohn’s disease for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Chronic Myelocytic Leukemia (CML) forecasted market share for ten years to 2023 segmented by seven major markets. In addition, the report also includes global forecast of epidemiology of Chronic Myelocytic Leukemia (CML) till 2023.

Key Coverage and Benefits

• The report will help in developing business strategies by understanding the trends shaping and driving the global Chronic Myelocytic Leukemia (CML) market.
• Identifying patient populations in the global “Chronic Myelocytic Leukemia (CML)market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the best opportunities for Chronic Myelocytic Leukemia (CML) therapeutics in each of the markets covered.
• To understand the future market competition in the global Chronic Myelocytic Leukemia (CML) therapeutics market and Insightful review of the key market drivers and barriers.

Scope

• Report covers the disease overview including etiology, path physiology, symptoms, diagnosis, disease management, and current treatment options.
• Marketed information including available prescription drugs, its patent and exclusivity details followed by drug sales till 2018.
• The Report also covers the detailed global historical and forecasted epidemiological data covering United States, EU5, Japan and rest of the word from 2013-2023.
• It also provides Chronic Myelocytic Leukemia (CML) for United States, EU5 and Japan from 2013 and forecasted Market to 2023.

【レポートの目次】

Table of Contents

• Chronic Myelocytic Leukemia (CML) overview
• Pathophysiology
• Symptoms of disease
• Etiology of disease
• Diagnosis of disease
• Treatment of disease
• Overview of Marketed drugs
• Drug Description
• Mechanism of Action
• Pharmacokinetics Properties
• Marketed Details
• Patent Information
• Patent Exclusivity Expiry Assessment United States (US)
• Patents Details
• Historical and Forecasted sales of marketed molecules in the Global Chronic Myelocytic Leukemia (CML) Market
• Global Epidemiology of Chronic Myelocytic Leukemia (CML) Forecasted to 2023
• Global Market (2013-2015)
• Global Forecasted Market (2016-2023)
• Global Market by Geography
• Market of US (2013-2015)
• Forecasted Market of US (2016-2023)
• Market of Europe
• Market of Germany (2013-2015)
• Forecasted Market of Germany (2016-2023)
• Market of United Kingdom (2013-2015)
• Forecasted Market of United Kingdom (2016-2023)
• Market of France (2013-2015)
• Forecasted Market of France (2016-2023)
• Market of Italy (2013-2015)
• Forecasted Market of Italy (2016-2023)
• Market of Spain (2013-2015)
• Forecasted Market of Spain (2016-2023)
• Market of Japan (2013-2015)
• Forecasted Market of Japan (2016-2023)
• Market of ROW (2013-2015)
• Forecasted Market of ROW (2016-2023)
• Appendix
• Report Methodology
• Consulting Services
• Disclaimer
• Report Purchase Options
• About DelveInsight

List of Tables

• Table 1: Drug Description
• Table 2: Drug, Marketed Details United States (US)
• Table 3: Drug, Patent Number Specific Patent Expiry in US (Year), 2015
• Table 4: Drug, Patent Details for US
• Table 5: Chronic Myelocytic Leukemia (CML) Drug Sales (USD Millions)-2023
• Table 6: Global Epidemiology of Chronic Myelocytic Leukemia (CML) (2013-2023)
• Table 7: Chronic Myelocytic Leukemia (CML) Global Market (USD Millions), (2013-2015)
• Table 8: Chronic Myelocytic Leukemia (CML) Global Market (USD Millions), (2016-2023)
• Table 9: Chronic Myelocytic Leukemia (CML) US Market (USD Millions), (2013-2015)
• Table 10: Chronic Myelocytic Leukemia (CML) US Market (USD Millions), (2016-2023)
• Table 11: Chronic Myelocytic Leukemia (CML) Germany Market (USD Millions), (2013-2015)
• Table 12: Chronic Myelocytic Leukemia (CML) Germany Market (USD Millions), (2016-2023)
• Table 13: Chronic Myelocytic Leukemia (CML) United Kingdom Market (USD Millions), (2013-2015)
• Table 14: Chronic Myelocytic Leukemia (CML) United Kingdom Market (USD Millions), (2016-2023)
• Table 15: Chronic Myelocytic Leukemia (CML) France Market (USD Millions), (2013-2015)
• Table 16: Chronic Myelocytic Leukemia (CML) France Market (USD Millions), (2016-2023)
• Table 17: Chronic Myelocytic Leukemia (CML) Italy Market (USD Millions), (2013-2015)
• Table 18: Chronic Myelocytic Leukemia (CML) Italy Market (USD Millions), (2016-2023)
• Table 19: Chronic Myelocytic Leukemia (CML) Spain Market (USD Millions), (2013-2015)
• Table 20: Chronic Myelocytic Leukemia (CML) Spain Market (USD Millions), (2016-2023)
• Table 21: Chronic Myelocytic Leukemia (CML) Japan Market (USD Millions), (2013-2015)
• Table 22: Chronic Myelocytic Leukemia (CML) Japan Market (USD Millions), (2016-2023)
• Table 23: Chronic Myelocytic Leukemia (CML) ROW Market (USD Millions), (2013-2015)
• Table 24: Chronic Myelocytic Leukemia (CML) ROW Market (USD Millions), (2016-2023)

List of Figures

• Figure 1: Chronic Myelocytic Leukemia (CML) Drug Sales (USD Millions)-2023
• Figure 2: Global Epidemiology of Chronic Myelocytic Leukemia (CML) (2013-2023)
• Figure 3: Chronic Myelocytic Leukemia (CML) Global Market (USD Millions), (2013-2015)
• Figure 4: Chronic Myelocytic Leukemia (CML) Global Market (USD Millions), (2016-2023)
• Figure 5: Chronic Myelocytic Leukemia (CML) US Market (USD Millions), (2013-2015)
• Figure 6: Chronic Myelocytic Leukemia (CML) US Market (USD Millions), (2016-2023)
• Figure 7: Chronic Myelocytic Leukemia (CML) Germany Market (USD Millions), (2013-2015)
• Figure 8: Chronic Myelocytic Leukemia (CML) Germany Market (USD Millions), (2016-2023)
• Figure 9: Chronic Myelocytic Leukemia (CML) United Kingdom Market (USD Millions), (2013-2015)
• Figure 10: Chronic Myelocytic Leukemia (CML) United Kingdom Market (USD Millions), (2016-2023)
• Figure 11: Chronic Myelocytic Leukemia (CML) France Market (USD Millions), (2013-2015)
• Figure 12: Chronic Myelocytic Leukemia (CML) France Market (USD Millions), (2016-2023)
• Figure 13: Chronic Myelocytic Leukemia (CML) Italy Market (USD Millions), (2013-2015)
• Figure 14: Chronic Myelocytic Leukemia (CML) Italy Market (USD Millions), (2016-2023)
• Figure 15: Chronic Myelocytic Leukemia (CML) Spain Market (USD Millions), (2013-2015)
• Figure 16: Chronic Myelocytic Leukemia (CML) Spain Market (USD Millions), (2016-2023)
• Figure 17: Chronic Myelocytic Leukemia (CML) Japan Market (USD Millions), (2013-2015)
• Figure 18: Chronic Myelocytic Leukemia (CML) Japan Market (USD Millions), (2015-2023)
• Figure 19: Chronic Myelocytic Leukemia (CML) ROW Market (USD Millions), (2013-2015)
• Figure 20: Chronic Myelocytic Leukemia (CML) ROW Market (USD Millions), (2016-2023)



【掲載企業】

• Novartis AG
• Bristol-Myers Squibb Company
• Pfizer Inc.
• Celgene Corporation
• Ariad Pharmaceuticals Inc.
• Teva Pharmaceutical Industries Ltd.
• Merck & Co. Inc.
• Sanofi
• F. Hoffmann-La Roche Ltd.
• Amgen Inc.

【レポートのキーワード】

慢性骨髄性白血病(CML)

★調査レポート[慢性骨髄性白血病(CML)治療薬の世界市場:市場インサイト、疫学、市場予測]販売に関する免責事項
★調査レポート[慢性骨髄性白血病(CML)治療薬の世界市場:市場インサイト、疫学、市場予測]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆